Cascade Prodrug Overview

  • Founded
  • 2009

Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $450K

  • Investors
  • 14

Cascade Prodrug General Information

Description

Developer of chemotherapy technology designed to treat a variety of solid tumor indications. The company's technology specializes in the advantage of tumor hypoxia and triggers drug conversion in the tumor where it's needed, thus limiting the exposure of healthy tissue to a potent cytotoxic agent, enabling cancer patients to experience an improved safety profile relative to currently approved chemotherapy agents.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Primary Office
  • Post Office Box 13020
  • Eugene, OR 97440
  • United States
+1 (541) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cascade Prodrug Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 06-Apr-2020 $450K 00.000 Completed Generating Revenue
6. Later Stage VC 03-Jun-2016 00000 00.000 Completed Generating Revenue
5. Later Stage VC 03-Apr-2015 0000 00.000 Completed Generating Revenue
4. Early Stage VC (Series A) 01-Apr-2013 00.000 00.000 Completed Generating Revenue
3. Grant 11-May-2012 00000 00000 Completed Generating Revenue
2. Early Stage VC 14-Feb-2012 $400K $400K Completed Generating Revenue
1. Grant 29-Oct-2010 $244K Completed Generating Revenue
To view Cascade Prodrug’s complete valuation and funding history, request access »

Cascade Prodrug Patents

Cascade Prodrug Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2681222-A1 Mannich base n-oxide drugs Active 19-Mar-2007 0000000000
CA-2681222-C Mannich base n-oxide drugs Active 19-Mar-2007 0000000000
EP-2136626-A4 Mannich base n-oxide drugs Inactive 19-Mar-2007 0000000000 0
EP-2136626-A1 Mannich base n-oxide drugs Inactive 19-Mar-2007 0000000000
US-20100016252-A1 Mannich base n-oxide drugs Active 19-Mar-2007 C07C291/04
To view Cascade Prodrug’s complete patent history, request access »

Cascade Prodrug Executive Team (4)

Name Title Board Seat Contact Info
Allan Cochrane Co-Founder, President, Board Member & Head of Corporate Development
John Nepute Chief Financial Officer
August Sick Co-Founder, Managing Director & Board Member
Eric Malek Chief Business Officer & Board Member
To view Cascade Prodrug’s complete executive team members history, request access »

Cascade Prodrug Board Members (8)

Name Representing Role Since
Allan Cochrane Cascade Prodrug Co-Founder, President, Board Member & Head of Corporate Development 000 0000
Armen Shanafelt Ph.D Self Board Member 000 0000
August Sick Cascade Prodrug Co-Founder, Managing Director & Board Member 000 0000
Eric Malek Cascade Prodrug Chief Business Officer & Board Member 000 0000
Lynnor Stevenson Ph.D Oregon Venture Fund Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Cascade Prodrug Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cascade Prodrug Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Elevate Capital Venture Capital Minority 000 0000 000000 0
Elijahu Shapira Angel (individual) Minority 000 0000 000000 0
Eric Boothe Angel (individual) Minority 000 0000 000000 0
Eric Doebele Angel (individual) Minority 000 0000 000000 0
Justin Curzi Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »